Today's Mistakes and Tomorrow's Wisdom in Development and Use of Biomarkers for Barrett's Esophagus.

Publikation

Today's Mistakes and Tomorrow's Wisdom in Development and Use of Biomarkers for Barrett's Esophagus.

Wissenschaftlicher Artikel/Review - 02.02.2022

Frei Nicola Fabian, Stachler Matthew D

Zitation

Frei N, Stachler M. Today's Mistakes and Tomorrow's Wisdom in Development and Use of Biomarkers for Barrett's Esophagus. Visc Med 2022; 38:173-181.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Visc Med 2022; 38

Veröffentlichungsdatum

02.02.2022

ISSN (Druck)

2297-4725

Seiten

173-181

Kurzbeschreibung/Zielsetzung

A histological diagnosis of dysplasia is our current best predictor of progression in Barrett's esophagus (BE), the precursor of esophageal adenocarcinoma (EAC). Despite periodic endoscopic surveillance and assessment of dysplastic changes, we fail to identify the majority of those who progress before the development of EAC, whereas the majority of patients undergo endoscopy without showing progression.